Dear COMPPARE team, participants, stakeholders and friends, As you may know, the COMPPARE study was made possible by an initial five-year, $11.9 million grant from the Patient-centered Outcomes Research Institute (PCORI) in 2017 to directly compare the potential benefits and harms of proton therapy to standard radiation therapy when…
A Message from Dr. Nancy Mendenhall Over the past two years, we have been searching for funding opportunities to support another 5 years of follow-up for the COMPPARE cohorts to provide all participants with a minimum of 8 years of follow-up. This spring a new funding opportunity was…
Dear COMPPARE team, participants, stakeholders and friends, From the moment enrollment was completed on October 31, 2022 we have turned our focus to retention, and I am pleased to report that retention (keeping patients actively on a study) and data collection rates have been excellent. I am immensely grateful…
A Message from Dr. Nancy Mendenhall Since COMPPARE was launched in 2017, new information has emerged that suggests there may be other differences in outcomes between photon and proton radiation in prostate cancer. We would like to answer as many of these questions as…
COMPPARE Newsroom Prostate cancer research news…
Dear COMPPARE team, participants, stakeholders and friends, I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! This is an exceptional accomplishment given the ongoing national healthcare…
A Message from Dr. Nancy Mendenhall I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! Read Dr. Mendenhall’s message. Partner Site…
The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…
Dear COMPPARE team, participants, stakeholders and friends, I am pleased to announce that on May 3, 2022, UH Seidman Cancer Center enrolled our 2,250th COMPPARE participant! This means we are now 75% of the way through the accrual process, an exceptional accomplishment given the ongoing challenges…
A Message from Dr. Nancy Mendenhall As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic…
